Credit Suisse’s Protara Therapeutics TARA Stock Holding History

Credit Suisse’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-250	Closed	-$116K	–	4629
2015 Q1	$116K	Buy	+250	New	+$110K	﹤0.01%	4204

Other funds holding TARA

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return

Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Credit Suisse's TARA Position: Q2 2015 in Review

Credit Suisse sold out of Protara Therapeutics (TARA) in Q2 2015, closing a stake of 250 shares — an estimated $116K sold.

Credit Suisse first reported a position in TARA in Q1 2015 and held it in 1 quarter. The position peaked at $116K in Q1 2015. 48 funds tracked by Wall St. Rank hold TARA as of Q2 2015.

Credit Suisse reported no remaining Protara Therapeutics position as of Q2 2015 after selling out during the quarter.
Credit Suisse sold 250 Protara Therapeutics shares in Q2 2015, an estimated $116K.
Credit Suisse first reported a position in Protara Therapeutics in Q1 2015 and held it in 1 quarter.
Credit Suisse's Protara Therapeutics position peaked at $116K in Q1 2015.
48 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2015.

Based on Credit Suisse's 13F filing for Q2 2015, filed 13 Aug 2015.